Completed PHASE1 INTERVENTIONAL 3-arm NCT02063555

Phase I Trial of DAR-901

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG

Sponsor: Aeras

Conditions Tuberculosis

Interventions BCG DAR-901 Sterile saline

Updated 6 times since 2017 Last updated: Aug 1, 2016 Started: Feb 28, 2014 Primary completion: Mar 31, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02063555, this PHASE1 trial focuses on Tuberculosis and remains completed. Sponsored by Aeras, it has been updated 6 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aeras
Dartmouth-Hitchcock Medical Center

Data source: Dartmouth-Hitchcock Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lebanon, United States